A University of California researcher examines a mammogram.
(Rich Pedroncelli/Associated Press)
MASS. MOVERS
ImmunoGen Inc. climbed 6.7 percent, the most since Aug. 15. The Waltham-based maker of anticancer drugs had its “buy’’ rating reiterated by a Canaccord Genuity analyst, George Farmer. He said that phase 2 trial results for ImmonoGen’s T-DM1 experimental drug for metastatic breast cancer were “striking’’ and support “commercial potential.’’ ImmunoGen is focused on developing targeted, antibody-based therapeutics.
© Copyright 2011 Globe Newspaper Company.
